Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib.
Gianluca TaronnaAlessandro LeonettiFilippo Gustavo Dall'OlioAlessandro RizzoClaudia ParisiSebastiano ButiPaola BordiStefano BrocchiRita GolfieriAndrea ArdizzoniNicola SverzellatiMarcello TiseoPublished in: Tumori (2021)
TAPO are benign pulmonary findings observed in patients treated with osimertinib. TAPO variability in terms of CT features can hinder the differential diagnosis with either osimertinib-related mild ILD or tumor progression. However, because TAPO are asymptomatic, it could be reasonable to continue therapy and verify the resolution of the CT findings at follow-up in selected cases.
Keyphrases
- interstitial lung disease
- small cell lung cancer
- epidermal growth factor receptor
- systemic sclerosis
- advanced non small cell lung cancer
- pulmonary hypertension
- image quality
- rheumatoid arthritis
- dual energy
- idiopathic pulmonary fibrosis
- computed tomography
- tyrosine kinase
- contrast enhanced
- positron emission tomography
- poor prognosis
- magnetic resonance imaging
- cerebral ischemia
- single molecule
- stem cells
- wild type
- pet ct
- replacement therapy